The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial (Q24629295)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial	scientific article

Statements

scholarly article

0 references

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial (English)

0 references

phase II clinical trial

0 references

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

Pauline Wimberger

13

object named as

Pauline Wimberger

0 references

Barbara Schmalfeldt

15

object named as

Barbara Schmalfeldt

0 references

Carsten Bokemeyer

17

object named as

Carsten Bokemeyer

0 references

author name string

Markus M Heiss

1

0 references

Pawel Murawa

2

0 references

Piotr Koralewski

3

0 references

Elzbieta Kutarska

4

0 references

Olena O Kolesnik

5

0 references

Vladimir V Ivanchenko

6

0 references

Alexander S Dudnichenko

7

0 references

Birute Aleknaviciene

8

0 references

Arturas Razbadauskas

9

0 references

Martin Gore

10

0 references

Elena Ganea-Motan

11

0 references

Tudor Ciuleanu

12

0 references

Alexander Schmittel

14

0 references

Alexander Burges

16

0 references

Horst Lindhofer

18

0 references

Angelika Lahr

19

0 references

Simon L Parsons

20

0 references

language of work or name

0 references

publication date

1 November 2010

0 references

International Journal of Cancer

0 references

127

0 references

9

0 references

2209-21

0 references

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

7 April 2017

Frequent EpCam protein expression in human carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

7 April 2017

The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

The pathogenesis of malignant ascites.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Malignant ascites: systematic review and guideline for treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Immunotherapy of malignant ascites with trifunctional antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Characterization of human IgG antimouse antibody in patients with B-cell malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

The current and future management of malignant ascites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

The past, the present and future of the OK-432 therapy for patients with malignant effusions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Malignant ascites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

New strategies for the management of malignant ascites.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

General aspects of cytokine-release syndrome: timing and incidence of symptoms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Intraperitoneal interferon in the management of malignant ascites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Malignant ascites. Clinical and experimental observations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

30 May 2018

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

28 November 2018

Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

28 November 2018

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

28 November 2018

Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

28 November 2018

The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A survey of practice in management of malignant ascites

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/IJC.25423

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24629295&oldid=1406033199"